Consilium Strategic Communications is a global leader in providing trusted, healthcare-focused strategic IR and financial PR counsel to corporations, Boards, senior decision makers and executives.

From offices in Europe and USA, Consilium Strategic Communications’ senior team provides cross-border comprehensive financial and corporate healthcare communications advice to some of the world’s most prominent corporations around-the-clock.

Client News

5/11/2015

Zealand interim report for the first nine months of 2015 (un-audited): Financial results on target with significant pipeline progress

Lyxumia® royalties and milestone revenue of DKK 20.6 million / EUR 2.7 million Net operating expenses of DKK 176.2 million / EUR 23.6 million for the period   Net result of DKK -183.7 million / EUR -24.6 million Financial guidance for 2015 unchanged     Significant pipeline progress in Q3 2015: Lixisenatide (Type 2 diabetes) application for regulatory approval in the US accepted for review by the FDA LixiLan (Type 2 diabetes) showed positive results in two Phase III trials and Sanofi expects regulatory submission in the US in Q4 2015 and in the EU in Q1 2016  Novel long-acting GLP-2 analogue, ZP1848, advanced into Phase II development for the treatment of Short Bowel Syndrome Stable glucagon analogue, ZP4207, showed positive results in a multiple-dose Phase Ib trial for better control of hypoglycemia  Copenhagen, 5 November 2015 – Zealand Pharma A/S (“Zealand”) (CVR no. 20 04 50 78) announces financial results on target for the first nine months of 2015, from 1 January to September 30, and reports that  significant product and pipeline milestones have been met and announced in Q3 2015.    Click to read more...

4/11/2015

Zealand is ready to take next steps in a diligent growth strategy for accelerated value creation: From peptide to patient

Zealand management yesterday presented the strategic direction for Zealand at a Capital Markets Day in New York Building on a strong trajectory, the company will focus to progress select proprietary specialist medicines through to registration, retaining full ownership and value control Pipeline expansion will continuously leverage Zealand’s leading-edge peptide expertise, combined with external innovation of new medicines Strong news flow from partnered and proprietary programs expected to continue through 2016   Click to read more...

4/11/2015

Oxford BioMedica - Business Update

Oxford, UK – 4 November 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, is pleased to announce the following business update. The Group continues to make good progress in line with its strategy across the business model, leveraging its extensive patent estate and know-how (intellectual property or “IP”) and its expertise and capabilities in the field of lentiviral vectors.  Recent developments across the three key components of the Group’s business model are summarised below.  The Group has recently introduced a numbering system for product development candidates (Central nervous system products will be numbered OXB-1XX, ophthalmology products OXB-2XX, and oncology candidates OXB-3XX). Click to read more...

4/11/2015

Advanced Medical Solutions Group plc - 510(k) Premarket notifications to market sutures in the US

Winsford, UK, 4 November 2015 - Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced woundcare specialist company, today announces that it has received notice of further  Premarket 510(k) approvals, successfully adding to its first US suture approval from early 2015, thereby covering the vast majority of the rest of the suture product portfolio. With only one more suture type still awaiting US market approval, the Group is now well positioned to launch a comprehensive range of sutures into the US in mid 2016 through a combination of its branded and unbranded routes to market.  Click to read more...

3/11/2015

Advanced Medical Solutions Group plc - FDA Approves Extended Product Claims for LiquiBand® Exceed™ Topical Skin Adhesive

Winsford, UK, 3 November 2015 - Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced woundcare specialist company, today announced that the FDA has approved two new product claims for the octyl formulation product, LiquiBand Exceed™ giving it a competitive advantage in the topical skin adhesive market.   Click to read more...

3/11/2015

Quanta appoints Dr Francesco Granata as Non-Executive Director

Alcester, Warwickshire, UK, 3 November 2015: Quanta Fluid Solutions Ltd (“Quanta” or the “Company”), a pioneer of advanced haemodialysis solutions, today announces the appointment of Dr Francesco Granata to the Company’s Board as an independent Non-Executive Director, with immediate effect. Click to read more...

3/11/2015

Biocartis to participate in key investor conferences in November 2015

Mechelen, Belgium, 3 November 2015: Biocartis (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announced that its Chief Executive Officer Rudi Pauwels, Deputy CEO & Managing Director Hilde Windels and Chief Financial Officer Ewoud Welten, will be participating in key investor conferences in November 2015: Click to read more...

3/11/2015

Data from Kiadis Pharma’s ongoing Phase II trial with ATIR101™ will be presented at the American Society of Hematology 2015 Annual Meeting

Amsterdam, The Netherlands, November 3, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that data from the Company’s ongoing Phase II clinical trial (NCT01794299/EudraCT 2012-004461-41) with its lead product ATIR101™ has been selected by the American Society of Hematology (ASH) Program Committee for presentation at the 57th Annual Meeting in Orlando, Florida on December 7, 2015.  Click to read more...

3/11/2015

MDxHealth Provides Third Quarter 2015 Business Update

Revenue for the first nine months up 44% to $11.9 million 67% increase in case volume from previous quarter and 30% year-on-year growth Expansion of uro-oncology product offering and global commercial strategy IRVINE, CA, and HERSTAL, BELGIUM – November 3, 2015 – MDxHealth SA (Euronext: MDXH.BR) today announced its third quarter 2015 Business Update for the period ended September 30, 2015. Click to read more...

2/11/2015

Mainstay Medical Applies for CE Mark for ReActiv8®

Dublin – Ireland, 2 November 2015 – Mainstay Medical International plc (Mainstay or the Company, Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain, announces it has submitted an application for CE Mark for ReActiv8. The submission represents a further key step towards commercialisation of ReActiv8 in Europe. Click to read more...

29/10/2015

Inivata Announces Appointment of Jeffrey Buchalter as Chairman

Cambridge, UK, 29 October 2015. Inivata Limited, a clinical cancer genomics company focused on harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment, announces the appointment of Jeffrey Buchalter as a Non-Executive Director and Chairman of the Board.  Click to read more...

29/10/2015

Zealand reports Lyxumia® royalty revenue for Q3 2015 and that Sanofi confirms expected next steps in the US regulatory process

Royalty revenue to Zealand from Sanofi’s sales of Lyxumia® (lixisenatide) ex-US amounted to DKK 7.1 million / EUR 0.9 million in Q3 2015, a 20% increase over Q3 2014 A US regulatory decision on lixisenatide by the FDA is expected in Q3 2016 Sanofi expects regulatory submission of LixiLan in Q4 2015 in the US and in Q1 2016 in Europe Copenhagen, 29 October 2015 – Zealand announces that royalty revenue on Sanofi’s global sales of Lyxumia® (lixisenatide) ex-US amounted to DKK 7.1 million / EUR 0.9 million for the period 1 July to 30 September 2015. This corresponds to an increase of 20% over the same period in 2014. Royalties were at the same level as for the previous quarter, after an increase of 12% from the first to the second quarter in 2015. Royalty revenue for the first nine months of 2015 amounted to DKK 20.5 million / EUR 2.7 million, which corresponds to an increase of 46% compared to the same period in 2014. Click to read more...

29/10/2015

Kiadis Pharma to participate in two partnering and investor conferences in November

Amsterdam, The Netherlands, October 29, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that the Company will participate in two upcoming partnering and investor conferences. Click to read more...

28/10/2015

Horizon Discovery Group plc Launches New E-Commerce Platform and Expands UK Headquarters

Key investment includes an integrated web-shop and Enterprise Resource Planning system to support further scale and revenue growth Expansion of UK footprint and operations in new purpose-built Cambridge facility Cambridge, UK, 28 October 2015: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Company”), the international life science company supplying genomics research tools and services that power genomics research and the development of personalized medicines, today announces the launch of its new eCommerce platform and integrated web-shop, and the expansion of its UK-based headquarters. Click to read more...

28/10/2015

Oxford BioMedica plc - GSK Exercises Option on Oxford BioMedica’s LentiVector® Technology Patents

Oxford, UK – 28 October 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, announces that GlaxoSmithKline PLC (GSK) has exercised an option to obtain a non-exclusive licence for two rare orphan disease indications under Oxford BioMedica's LentiVector® platform technology patents.  This follows an agreement signed between GSK and the Group in December 2013.  Click to read more...

28/10/2015

Epistem Holdings - Preliminary Results for the year ended 30 June 2015

Epistem Holdings Plc (LSE: EHP) (“Epistem” or “the Company”), the personalised medicine and biotechnology company, today announces its preliminary results for the year to 30 June 2015.   Click to read more...

27/10/2015

Midatech selects Fujitsu to provide IT solutions

Midatech Pharma (AIM: MTPH), the international specialty pharmaceutical company with a diversified portfolio of high-value products in development, today announced that it has selected Fujitsu to provide IT solutions for all of its sites, globally. Click to read more...

27/10/2015

Biocartis receives € 1.4M grant for development of innovative liquid biopsy tests

Mechelen, Belgium, 27 October 2015: Biocartis (Euronext Brussels: BCART), an innovative molecular diagnostics company, announces that it has received a € 1.4M grant from the Flemish Agency for Innovation by Science and Technology (IWT). Biocartis will use this grant to support the research and development of liquid biopsy versions of its solid tumour biopsy BRAF and KRAS diagnostic tests for melanoma and colorectal cancer, as well as research towards improved liquid biopsy methodologies.  Click to read more...

26/10/2015

Quanta Treats First Patients with Advanced Haemodialysis System SC+

Quanta Fluid Solutions Ltd, a pioneer of advanced haemodialysis solutions, today announces it has successfully treated the first patients with SC+, its portable, cartridge-based haemodialysis system. The news was reported on by BBC Breakfast. To view the news item, please follow this link. Click to read more...

23/10/2015

Celyad - First US Patent Covering Allogeneic Chimeric Antigen Receptor T Cells (“CAR-T”) Modified to Reduce Immunogenicity is Awarded to Celyad

Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immune-oncology today announced the issuance of United States Patent No. 9,181,527 (“US Patent 9,181,527”) relating to allogeneic human primary T-Cells that are engineered to be T-Cell Receptor (TCR)-deficient and express a Chimeric Antigen Receptor (CAR).   Click to read more...

Consilium News

26/4/2016

Communicating how cutting-edge drug treatments benefit everyone is a tough challenge

One of our most important comms challenges is to convince governments and regulators that costly cutting-edge treatments are worth it. Click to read more...

2/3/2015

21 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events’ Pharma Summit 2015

21 Years of Debate: The Pharmaceutical Industry Convenes at The Economist Events’ Pharma Summit 2015 to Discuss The Dawn of a New Era for the Industry Click to read more...

23/2/2015

The Economist Events’ Pharma Summit 2015: The dawn of a new era

Challenges impacting the world of pharma as well as the innovation required to face them   Tweet your questions ahead of the Pharma Summit 2015 via @EconomistEvents #pharmasummit Click to read more...

4/2/2015

Consilium Strategic Communications Advises on First European Healthcare IPO of 2015

Bone Therapeutics Raises EUR 32.2 Million in 2.5x Oversubscribed Euronext Flotation Click to read more...

24/4/2014

Preparation, Preparation, Preparation: Communicating in a Crisis

In a recent article for Scrip Intelligence (8 April 14), Consilium Strategic Communications’ co-founding partner, Amber Bielecka, was consulted on how companies should navigate communications in a crisis situation.  In the article “Surviving a Scandal: How to Expect the Unexpected”, Amber cites Consilium’s core mantra for healthcare clients to ensure they do not get caught out in a crisis situation: Preparation, Preparation, Preparation. Click to read more...

27/3/2014

Consilium Strategic Communications Advises Horizon Discovery Group plc on its AIM Listing

London, 27 March 2014 - Consilium Strategic Communications, a global leader in strategic healthcare communications, is delighted to have advised upon the successful IPO of Horizon Discovery which listed on the AIM market of the London Stock Exchange today. Click to read more...

14/3/2014

Consilium Strategic Communications Supports The Economist Events’ Pharma Summit 2014

Consilium Strategic Communications, as The Economist Events’ 20th Annual Pharma Summit Official PR Agency, yesterday supported for the fourth time what has become known as the premier event for the industry’s most high-profile leaders to debate a number of topical issues facing the sector. Sponsored by EY, this year’s theme, ‘Reinventing Business Models and Markets’, observed the challenges the pharmaceutical industry faces in the current climate and the future of life science innovation. Click to read more...

12/2/2014

Consilium Strategic Communications Strengthens Team and Appoints Ex-Journalist Jessica Hodgson as a New Consultant

Consilium Strategic Communications, a global leader in healthcare financial public and investor relations, today announces the appointment of Jessica Hodgson as a Consultant. Click to read more...

23/1/2014

Consilium Supports BIA Next Generation UK Healthcare Event

Six up-and-coming private UK healthcare companies will present at today’s Next Generation UK Healthcare Showcase. The event co-hosted by the BioIndustry Association (BIA), Consilium Strategic Communications, Panmure Gordon & Co and Pinsent Masons, aims to provide the wider investor community with further insight and understanding of the quality of firms, science and management teams in the sector. Click to read more...

16/12/2013

Consilium Strategic Communications Forms Partnership with US Specialist Healthcare Strategic IR and PR advisor

Consilium Strategic Communications, Europe and Asia’s only dedicated strategic communications advisor for the healthcare sector, has partnered with Rx Communications Group, a leading US-based, healthcare-focused, financial communications firm, to formally expand its international reach within the United States. Click to read more...

19/11/2013

Consilium Strategic Communications Holds Annual Healthcare Conference

Consilium Strategic Communications, Europe’s only dedicated strategic communications advisor for the healthcare sector, is holding its Annual Healthcare Conference in association with Covington & Burling LLP in London today.  Click to read more...

9/9/2013

CSC Appoints New Partner & Opens First Office in Asia

Consilium Strategic Communications, Europe and Asia’s only dedicated strategic communications advisor for the healthcare sector, announces the appointment of Emma Thompson as a Partner and the opening of its first office in Asia.  Click to read more...

25/7/2013

Company Launch

Consilium Strategic Communications (Consilium), Europe’s only dedicated strategic communications advisor for the healthcare sector, has launched today as a spin-off from M:Communications. Click to read more...

Careers

Join us at Consilium

Consilium Strategic Communications welcomes prospective candidates and interns to share a copy of their résumé and a cover letter via email.

Sign up

Register for news and updates

   
logo

Design By Brandcast Media